Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L6 pseudogene 32 (RPL6P32) is a non-functional genomic element in humans, categorized as a processed pseudogene. It is derived from the ribosomal protein L6 (RPL6) gene, which encodes a structural protein of the large 60S ribosomal subunit involved in protein synthesis[2][7]. Unlike its parent gene, RPL6P32 does not code for a functional ribosomal protein and has no established role in cellular processes or diseases. Pseudogenes like RPL6P32 are common remnants within the genome, originating from duplication or retrotransposition events, and are generally non-coding[3]. There are no reports of biological function, disease involvement, drug interaction, or therapeutic relevance for RPL6P32.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L6 pseudogene 32 (RPL6P32).